SynthesisFrontiers in pharmacology2025
Effect of antioxidants on primary open-angle glaucoma: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Neuroinflammation and Oxidative Stress to Slow Neurodegeneration in the Visual System.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: Primary open-angle glaucoma is a major global cause of vision loss, severely impacting quality of life. Although the need for effective treatments is widely recognized, the efficacy and safety of antioxidants remain uncertain. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of antioxidants in treating patients with primary open-angle glaucoma. Methods: We reviewed studies from PubMed, Embase, Cochrane Library, and Web of Science published up to 30 November 2024. Eligible studies included adults aged 18-80 years with primary open-angle or normal-tension glaucoma, comparing antioxidant treatment with placebo or comparing a combination of topical treatment and antioxidants with topical treatment alone. Only randomized controlled trials and crossover trials were included. Studies involving secondary glaucoma, ocular inflammation, trauma, or severe systemic disease were excluded, as were nonhuman studies. Of the 518 studies, 15 (2.9%) met the final criteria. Data abstraction and quality assessment followed established guidelines for rigor and transparency. The study outcomes-intraocular pressure, visual field deterioration, ocular blood circulation, blood pressure, and adverse effects-were chosen to evaluate the efficacy and safety of antioxidant treatments in primary open-angle glaucoma. Results: Analysis of 15 studies showed that antioxidant supplementation reduces intraocular pressure, improves visual field mean deterioration, and enhances ocular blood circulation in patients with primary open-angle glaucoma. No significant differences were observed in blood pressure or adverse effects between the treatment and placebo groups. Conclusion: This meta-analysis highlights the potential role of antioxidants as a safe and effective therapeutic option for patients with primary open-angle glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.